Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Marathon Oil (MRO): A 'Prudent' speculation


Bookmark and Share
by John Buckingham, editor The Prudent Speculator

John BuckinghamWe think there is too much risk to owning pure refiners in this environment.

However, there is one company with a valuation now hurt by its refining exposure, but that is shifting upstream in a way that makes the eventual mix worth owning now: Marathon Oil (MRO).

Since the turn of the century, Marathon Oil has generated an average of 85% of its revenue from refining. And profit coming from the upstream division was weighted by taxes and royalties.

As a result, the company has traditionally been valued much more like a refiner than a true integrated oil company.
Advertisement
Banner

Its price to sales ratio of 0.4 is much closer to the independent refiner multiple than the 0.7 average afforded to the integrated companies that Marathon counts as its peers.

We do not however, want to discount the refining operations entirely. In the four years since margins on operating income per barrel of throughput topped in 2006,

Marathon has averaged the second-best marks in the industry. And the company is still posting healthy profits, even though every other refiner has posted at least two consecutive quarterly losses.

Completion of a massive expansion of the company’s Garyville refinery earlier this year increased its capacity almost 75% and its Detroit refinery is beefing up bitumen refining capacity, providing vertical synergy with the company’s oil sands operations.

The step change in Marathon’s valuation should occur when investors better understand the company’s rising leverage to higher oil prices. Currently, corporate and special taxes total 80% on its Norway project. In Libya, earnings caps resulted in a 93% income tax rate in 2009.

Similar situations exist for many other international properties. A pipeline full of projects in more normal tax jurisdictions is set to change that dynamic. First up is the Droshky project set to come online later this year.

The high pressure acreage in the Gulf of Mexico that will see greater production in the first few years can be a bridge to other production increases. Marathon is beginning to ramp production in North Dakota.

Potential upside could also come from further development and debottlenecking of the Athabasca tar sands, which are 20% owned by Marathon. The largest oil sands development in Canada, Athabasca operations have struggled immensely with high costs and abnormal downtime.

We think healthier returns on these new projects may be just the thing needed to clear up Marathon’s cloudy valuation.

Learn more about this financial newsletter at The Prudent Speculator.

Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary